Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages

Journal of Lipid Research

Volumn 55, Issue 12, 2015, Pages 2501-2508

  Feingold, Kenneth R ^a   Moser, Arthur ^a   Shigenaga, Judy K ^a   Grunfeld, Carl ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diacylglycerol transferase; G protein coupled receptor 109A; G proteins; Hydroxycarboxylic acid 2 receptor; Lipopolysaccharide; Sytokines; Triglycerides

Indexed keywords

ADAPTOR PROTEIN; BETA INTERFERON; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; HYDROXYCARBOXYLIC ACID 2 RECEPTOR; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; NIACIN RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; RECEPTOR; TOLL LIKE RECEPTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ZYMOSAN; HCAR2 PROTEIN, MOUSE; NICOTINIC RECEPTOR;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; FEMALE; INFLAMMATION; INTRACELLULAR SIGNALING; LIPOGENESIS; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; DISEASE MODEL; GENETICS; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; IMMUNOLOGY; INTRAABDOMINAL FAT; LIPID METABOLISM; METABOLISM; MYCOSIS; PATHOLOGY; RNA INTERFERENCE; TRANSFORMED CELL LINE; UPREGULATION; VIRUS INFECTION;

3T3-L1 CELLS; ANIMALS; CELL LINE, TRANSFORMED; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MYCOSES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UP-REGULATION; VIRUS DISEASES;

EID: 84919778891     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M050955     Document Type: Article

References (37)

1. Carlson, L. A. 2005. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258: 94-114 .
2. Guyton, J. R. 2007. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr. Opin. Lipidol. 18: 415-420 .
3. Kamanna, V. S., and M. L. Kashyap. 2008. Mechanism of action of niacin. Am. J. Cardiol. 101: 20B-26B .
4. Butcher, R. W., C. E. Baird, and E. W. Sutherland. 1968. Effects of lipolytic and antilipolytic substances on adenosine 3',5'-monophosphate levels in isolated fat cells. J. Biol. Chem. 243: 1705-1712 .
5. Carlson, L. A. 1963. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med. Scand. 173: 719-722 .
6. Tunaru, S., J. Kero, A. Schaub, C. Wufka, A. Blaukat, K. Pfeffer, and S. Offermanns. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9: 352-355 .
7. Holm, C. 2003. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem. Soc. Trans. 31: 1120-1124 .
8. McKnight, G. S., D. E. Cummings, P. S. Amieux, M. A. Sikorski, E. P. Brandon, J. V. Planas, K. Motamed, and R. L. Idzerda. 1998. Cyclic AMP, PKA, and the physiological regulation of adiposity. Recent Prog. Horm. Res. 53: 139-159; discussion 160-131.
9. Lorenzen, A., C. Stannek, A. Burmeister, I. Kalvinsh, and U. Schwabe. 2002. G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem. Pharmacol. 64: 645-648.
10. Lorenzen, A., C. Stannek, H. Lang, V. Andrianov, I. Kalvinsh, and U. Schwabe. 2001. Characterization of a G protein-coupled receptor for nicotinic acid. Mol. Pharmacol. 59: 349-357 .
11. Davidson, M. H. 2008. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am. J. Cardiol. 101: 14B-19B.
12. Benyó, Z., A. Gille, J. Kero, M. Csiky, M. C. Suchánková, R. M. Nüsing, A. Moers, K. Pfeffer, and S. Offermanns. 2005. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115: 3634-3640.
13. Hanson, J., A. Gille, S. Zwykiel, M. Lukasova, B. E. Clausen, K. Ahmed, S. Tunaru, A. Wirth, and S. Offermanns. 2010. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Invest. 120: 2910-2919.
14. Pike, N. B. 2005. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J. Clin. Invest. 115: 3400-3403 .
15. Soga, T., M. Kamohara, J. Takasaki, S. Matsumoto, T. Saito, T. Ohishi, H. Hiyama, A. Matsuo, H. Matsushime, and K. Furuichi. 2003. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303: 364-369.
16. Wise, A., S. M. Foord, N. J. Fraser, A. A. Barnes, N. Elshourbagy, M. Eilert, D. M. Ignar, P. R. Murdock, K. Steplewski, A. Green, et al. 2003. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278: 9869-9874.
17. Offermanns, S. 2006. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol. Sci. 27: 384-390 .
18. Soudijn, W., I. van Wijngaarden, and A. P. Ijzerman. 2007. Nicotinic acid receptor subtypes and their ligands. Med. Res. Rev. 27: 417-433.
19. Schaub, A., A. Futterer, and K. Pfeffer. 2001. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur. J. Immunol. 31: 3714-3725.
20. Wanders, D., E. C. Graff, and R. L. Judd. 2012. Effects of high fat diet on GPR109A and GPR81 gene expression. Biochem. Biophys. Res. Commun. 425: 278-283.
21. Zandi-Nejad, K., A. Takakura, M. Jurewicz, A. K. Chandraker, S. Offermanns, D. Mount, and R. Abdi. 2013. The role of HCA2 (GPR109A) in regulating macrophage function. FASEB J. 27: 4366-4374.
22. Digby, J. E., E. McNeill, O. J. Dyar, V. Lam, D. R. Greaves, and R. P. Choudhury. 2010. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis. 209: 89-95.
23. Patton, J. S., H. M. Shepard, H. Wilking, G. Lewis, B. B. Aggarwal, T. E. Eessalu, L. A. Gavin, and C. Grunfeld. 1986. Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc. Natl. Acad. Sci. USA. 83: 8313-8317 .
24. Tang, W., A. Walsh, and I. Tabas. 1999. Macrophage-targeted CTP:phosphocholine cytidylyltransferase (1-314) transgenic mice. Biochim. Biophys. Acta. 1437: 301-316.
25. Kawai, T., and S. Akira. 2006. TLR signaling. Cell Death Differ. 13: 816-825.
26. Noman, A. S., N. Koide, F. Hassan, I. I-E. Khuda, J. Dagvadorj, G. Tumurkhuu, S. Islam, Y. Naiki, T. Yoshida, and T. Yokochi. 2009. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun. 15: 33-41.
27. Clark, K., L. Plater, M. Peggie, and P. Cohen. 2009. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J. Biol. Chem. 284: 14136-14146 .
28. Hehner, S. P., M. Heinrich, P. M. Bork, M. Vogt, F. Ratter, V. Lehmann, K. Schulze-Osthoff, W. Droge, and M. L. Schmitz. 1998. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J. Biol. Chem. 273: 1288-1297 .
29. Feingold, K. R., J. K. Shigenaga, M. R. Kazemi, C. M. McDonald, S. M. Patzek, A. S. Cross, A. Moser, and C. Grunfeld. 2012. Mechanisms of triglyceride accumulation in activated macrophages. J. Leukoc. Biol. 92: 829-839 .
30. Nicolaou, G., and C. Erridge. 2010. Toll-like receptor-dependent lipid body formation in macrophage foam cell formation. Curr. Opin. Lipidol. 21: 427-433 .
31. Gaidarov, I., X. Chen, T. Anthony, D. Maciejewski-Lenoir, C. Liaw, and D. J. Unett. 2013. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Cell. Signal. 25: 2003-2016 .
32. Lukasova, M., C. Malaval, A. Gille, J. Kero, and S. Offermanns. 2011. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest. 121: 1163-1173 .
33. Rubic, T., M. Trottmann, and R. L. Lorenz. 2004. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol. 67: 411-419 .
34. AIM-HIGH Investigators. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267 .
35. HPS2-THRIVE Collaborative Group. 2013. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34: 1279-1291 .
36. HPS2-THRIVE Collaborative Group. 2014. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371: 203-212 .
37. Canner, P. L., K. G. Berge, N. K. Wenger, J. Stamler, L. Friedman, R. J. Prineas, and W. Friedewald. 1986. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8: 1245-1255 .